Evidence map›Paper›PMID 35177657›Full record

ArticleNature communications2022

TrkB agonist antibody ameliorates fertility deficits in aged and cyclophosphamide-induced premature ovarian failure model mice.

Xunsi Qin, Yue Zhao, Tianyi Zhang, Chenghong Yin, Jie Qiao, Wei Guo, Bai Lu

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers.

0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed
23.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

71 citing papers in PubMed, 124 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article

11 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Xunsi QinSchool of Pharmaceutical Sciences, IDG/McGovern Institute for Brain Research, Joint Graduate Program of Peking-Tsinghua-NIBS, Tsinghua University, Beijing, 100084, China.ORCID http://orcid.org/0000-0002-5869-8873
Yue ZhaoCenter for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing, 100191, China.ORCID http://orcid.org/0000-0002-3016-9654
Tianyi ZhangSchool of Pharmaceutical Sciences, IDG/McGovern Institute for Brain Research, Joint Graduate Program of Peking-Tsinghua-NIBS, Tsinghua University, Beijing, 100084, China.
Chenghong YinDepartment of Internal Medicine, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, 100026, China.
Jie QiaoCenter for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing, 100191, China.ORCID http://orcid.org/0000-0003-2126-1376
Wei GuoSchool of Pharmaceutical Sciences, IDG/McGovern Institute for Brain Research, Joint Graduate Program of Peking-Tsinghua-NIBS, Tsinghua University, Beijing, 100084, China. wguo@tsinghua.edu.cn.ORCID http://orcid.org/0000-0002-9937-7152
Bai LuSchool of Pharmaceutical Sciences, IDG/McGovern Institute for Brain Research, Joint Graduate Program of Peking-Tsinghua-NIBS, Tsinghua University, Beijing, 100084, China. bai_lu@tsinghua.edu.cn.ORCID http://orcid.org/0000-0001-5418-9759
Capital Medical University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Premature ovarian failure (POF) is a leading cause of women's infertility without effective treatment. Here we show that intravenous injection of Ab4B19, an agonistic antibody for the BDNF receptor TrkB, penetrates into ovarian follicles, activates TrkB signaling, and promotes ovary development. In both natural aging and cyclophosphamide-induced POF models, treatment with Ab4B19 completely reverses the reduction of pre-antral and antral follicles, and normalizes gonadal hormone. Ab4B19 also attenuates gonadotoxicity and inhibits apoptosis in cyclophosphamide-induced POF ovaries. Further, treatment with Ab4B19, but not BDNF, restores the number and quality of oocytes and enhances fertility. In human, BDNF levels are high in granulosa cells and TrkB levels increase in oocytes as they mature. Moreover, BDNF expression is down-regulated in follicles of aged women, and Ab4B19 activates TrkB signaling in human ovary tissue ex vivo. These results identify TrkB as a potential target for POF with differentiated mechanisms, and confirms superiority of TrkB activating antibody over BDNF as therapeutic agents.

Indexed as

Fertility Agents, FemaleMembrane GlycoproteinsOvaryPrimary Ovarian InsufficiencyReceptor, trkBAdultAgingAnimalsApoptosisBrain-Derived Neurotrophic FactorCell Line, TumorCyclophosphamideDisease Models, AnimalFemaleFertilityHumansBDNF protein, humanBdnf protein, mouseBrain-Derived Neurotrophic FactorCyclophosphamideFertility Agents, FemaleMembrane GlycoproteinsNtrk2 protein, mouseReceptor, trkBtropomyosin-related kinase-B, human

Identifiers

PMID35177657
PMCPMC8854395
OpenAlexW4213333283

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.